A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 500 participants.
Also called NCT06481891
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 500 participants
- Sponsor
- Registry
-
NCT06481891
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Belgium, Brazil, Bulgaria, Croatia, Czechia, France, Georgia, Germany, Hungary, Israel, Italy, Poland, Portugal, Romania, Serbia, Sweden, United Kingdom
- Registry status
- Active, not recruiting
Technical summary
Registry record NCT06481891. Randomized; quadruple masking; primary purpose treatment. Start 2024-09-24 (actual); primary completion 2027-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy
- Acronym
- SONATA-HCM
- Condition
- Obstructive Cardiomyopathy, Hypertrophic
- Condition
- Non-obstructive Hypertrophic Cardiomyopathy
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Placebo
- Lead sponsor
- Lexicon Pharmaceuticals
Record details
- Record id
cardio:ct-nct06481891- Content hash
d493256891ec6be3b24827fc80c2646989ed78a62faf207ddcc2d0d81799b545